Quoin Pharmaceuticals (QNRX) 20-F 19 Mar 18 2017 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017shares
Document and Entity Information [Abstract]
Entity Registrant Name	Cellect Biotechnology Ltd.
Entity Central Index Key	1,671,502
Trading Symbol	APOP
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Fiscal Period Focus	FY
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	120,140,659

Consolidated Balance Sheets

Consolidated Balance Sheets ₪ in Thousands, $ in Thousands	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)
CURRENT ASSETS:
Cash and cash equivalents	₪ 13,734	$ 3,961	₪ 6,279
Short term deposits			19,660
Marketable securities	13,999	4,038	4,997
Other receivables	818	236	1,461
Current assets	28,551	8,235	32,397
LONG-TERM ASSETS:
Restricted cash	305	88	140
Other Long term receivables	173	50
Property, plant and equipment, net	1,344	388	1,373
Non-current assets	1,822	526	1,513
Assets	30,373	8,761	33,910
CURRENT LIABILITIES:
Trade payables	1,703	491	1,401
Other payables	2,396	691	2,084
Current liabilities	4,099	1,182	3,485
NON CURRENT LIABILITIES:
Warrants to ADS	7,422	2,141	1,938
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS' EQUITY :
Ordinary shares of no par value: Authorized: 500,000,000 shares at December 31, 2016, and 2017, Issued and outstanding: 107,628,485*) and 120,185,659*) shares as of December 31, 2016 and 2017, respectively.
Additional Paid In Capital	82,839	23,894	67,414
Share-based payments	9,381	2,706	6,217
Treasury shares	(9,425)	(2,718)	(9,425)
Accumulated deficit	(63,943)	(18,444)	(35,719)
Equity	18,852	5,438	28,487
Equity and liabilities	₪ 30,373	$ 8,761	₪ 33,910

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - ₪ / shares		Dec. 31, 2017	Dec. 31, 2016
Statement of financial position [Abstract]
Ordinary shares, par value
Ordinary shares, authorized		500,000,000	500,000,000
Ordinary shares, issued	[1]	120,140,659	107,583,485
Ordinary shares, outstanding	[1]	120,140,659	107,583,485
Treasury shares		2,641,693	2,641,693
[1]	Net of 2,641,693 treasury shares of the Company, held by the Company.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)₪ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016ILS (₪)₪ / sharesshares	Dec. 31, 2015ILS (₪)₪ / sharesshares
Statement of comprehensive income [Abstract]
Research and development expenses, net	₪ 11,503	$ 3,318	₪ 8,256	₪ 5,893
General and administrative expenses	12,930	3,729	7,968	4,204
Other Income			(280)
Total operating expenses	24,433	7,047	15,944	10,097
Operating loss	24,433	7,047	15,944	10,097
Financial income	(101)	(29)	(660)	(4)
Financial expenses	3,892	1,123	33	79
Total Comprehensive loss	₪ 28,224	$ 8,141	₪ 15,317	₪ 10,172
Loss per share
Basic and diluted loss per share | (per share)	₪ 0.252	$ 0.073	₪ 0.168	₪ 0.137
Basic and diluted loss per ADS | (per share)	₪ 5.04	$ 1.46	₪ 3.36	₪ 2.74
Weighted average number of shares outstanding used to compute basic and diluted loss per share	111,968,663	111,968,663	91,128,516	74,475,109

Statements of Changes in Equity

Statements of Changes in Equity ₪ in Thousands, $ in Thousands	ILS (₪)	USD ($)	Share capitalILS (₪)	Share capitalUSD ($)	Additional paid in capitalILS (₪)	Additional paid in capitalUSD ($)	Treasury sharesILS (₪)	Treasury sharesUSD ($)	Share based paymentsILS (₪)	Share based paymentsUSD ($)	Accumulated deficitILS (₪)	Accumulated deficitUSD ($)
Balance at Dec. 31, 2014	₪ 12,959				₪ 30,904		₪ (9,425)		₪ 1,710		₪ (10,230)
Issuance of ADS net of issue costs	6,292				5,596				696
Share-based payment	1,318								1,318
Exercise of share options and warrants	104				225				(121)
Total comprehensive loss	(10,172)										(10,172)
Balance at Dec. 31, 2015	10,501				36,725		(9,425)		3,603		(20,402)
Issuance of ADS net of issue costs	31,744				30,682				1,062
Share-based payment	1,552								1,552
Exercise of share options and warrants	7				7
Total comprehensive loss	(15,317)										(15,317)
Balance at Dec. 31, 2016	28,487				67,414		(9,425)		6,217		(35,719)
Issuance of ADS net of issue costs	11,773				11,693				80
Share-based payment	5,384				642				4,742
Exercise of share options and warrants	1,432				2,470				(1,038)
Expiration of share options					620				(620)
Total comprehensive loss	(28,224)	$ (8,141)									(28,224)
Balance at Dec. 31, 2017	₪ 18,852	$ 5,438			₪ 82,839	$ 23,894	₪ (9,425)	$ (2,718)	₪ 9,381	$ 2,706	₪ (63,943)	$ (18,444)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)	Dec. 31, 2015ILS (₪)
Cash Flows from Operating Activities:
Total Comprehensive Loss	₪ (28,224)	$ (8,141)	₪ (15,317)	₪ (10,172)
Adjustments to profit and loss items:
Net financing expenses	532	154	134	69
Loss (Gain) from revaluation of financial assets presented at fair value through profit and loss	139	40	(106)	(2)
Depreciation and capital loss from sale of property, plant and equipment	372	107	350	71
Share-based payment	5,384	1,553	1,552	1,318
Changes in fair value of Traded and Non Traded Warrants To ADS	3,003	866	(1,235)
Adjustments to profit and loss	9,430	2,720	695	1,456
Changes in asset and liability items:
Decrease (increase) in other receivables	470	136	(1,049)	(328)
Increase in other payables	407	117	1,259	1,333
Operating activities for changes in asset and liability	877	253	210	1,005
Cash paid and received during the year for:
Interest received	147	42		1
Cash paid and received during the year				1
Net cash used in operating activities	(17,770)	(5,126)	(14,412)	(7,710)
Cash Flows from Investing Activities:
Proceeds received from the sale of fixed assets			95	77
Short term deposits, net	19,530	5,633	(19,530)
Restricted deposit	(165)	(47)	(120)
Marketable securities measured at fair value through profit and loss, net	(9,008)	(2,599)	2,808	3,430
Purchase of property, plant and equipment	(266)	(77)	(1,265)	(332)
Net cash provided by (used in) investing activities	10,091	2,910	(18,012)	3,175
Cash Flows from Financing Activities:
Exercise of warrants and stock options into shares	1,432	414	7	104
Issuance of share capital and warrants, net of issue costs (see note 11)	14,381	4,148	34,917	6,292
Net cash provided by financing activities	15,813	4,562	34,924	6,396
Exchange differences on balances of cash and cash equivalents	(679)	(196)	(134)	(70)
Increase in cash and cash equivalents	7,455	2,150	2,366	1,791
Balance of cash and cash equivalents at the beginning of the year	6,279	1,811	3,913	2,122
Balance of cash and cash equivalents at the end of the year	13,734	3,961	6,279	3,913
(a) Non-cash activities:
Purchase of property, plant and equipment	77	22	58	692
Issuance costs	₪ 127	$ 37

General

General	12 Months Ended
	Dec. 31, 2017
General [Abstract]
GENERAL	NOTE 1:- GENERAL a. Cellect Biotechnology Ltd. (formerly Cellect Biomed Ltd.) (the "Company" or "Cellect") is incorporated in Israel. Cellect and its subsidiary, Cellect Biotherapeutics Ltd. (the "Subsidiary") are engaged in the development of an innovative, unique technology that enables the biological filtering and commercialization of stem cells. Cellect’s American Depository Shares (“ADSs”) and certain warrants to purchase ADSs are listed for trading on the NASDAQ Capital Market. Each ADS represents 20 ordinary shares. On May 29, 2017, the Company announced that it received approval of the Israeli court to voluntarily delist the Company's ordinary shares from the Tel-Aviv Stock Exchange (TASE) in accordance with Section 350 to the Israeli Companies Law. The court approval followed the approval of the Company's shareholders on May 9, 2017. On June 7, 2017, the TASE announced that the last trading day in Tel Aviv will be on September 3, 2017, and that the de-listing date will be on September 5, 2017. As a result, on September 5, 2017, the Company's ordinary shares were voluntarily delisted from TASE. The ordinary shares of the Company continue to be listed on the NASDAQ Capital Market in the form of ADSs. b. Going Concern The accompanying financial statements have been prepared in conformity with International Financial Reporting Standards (IFRS), assuming that the Company will continue to operate as a going concern. During the year ended December 31, 2017, the Company incurred a net loss of NIS 28,224 ($8,141) and had negative cash flows from operating activities of NIS 17,770 ($5,126). In addition, the Company had an accumulated deficit of NIS 63,943 ($18,444) at December 31, 2017. The Company's management plans to seek additional equity financing. The Company believes its current capital resources are sufficient to support its operations through the end of the first quarter of 2019. The Company’s activities since inception have consisted of raising capital and performing research and development activities. As of December 31, 2017, principal commercial operations have not commenced. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations, if any, are dependent on future events, including, among other things, its ability to obtain marketing approval from regulatory authorities and access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel and develop strategic alliances. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities. To fund its capital needs, the Company plans to raise funds through equity or debt financings or other sources, such as strategic partnerships and alliance and licensing arrangements, and in the long term, from the proceeds from sales. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern. In addition, please refer to note 16. c. The Company currently relies on a single source supplier for one of the components used in R&D process.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The following accounting policies have been applied consistently in the consolidated financial statements for all periods presented, unless otherwise stated. a. Basis of presentation of the financial statements: These financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"). The Company's financial statements have been prepared on a cost basis, except for marketable securities and liability related to warrants that are measured at fair value through profit or loss. The Company has elected to present profit or loss items using the "function of expense" method. The Company's operating cycle is one year. b. Consolidated financial statements: The consolidated financial statements include the financial statements of companies that the Company controls (subsidiaries). Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases. The financial statements of the Company and its subsidiaries (the "Group") are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intercompany balances and transactions and gains or losses resulting from intragroup transactions are eliminated in full in the consolidated financial statements. c. Functional currency, reporting currency and foreign currency: 1. Functional currency and reporting currency: The reporting and the functional currency of the Company is the New Israeli Shekel (“NIS”). The Company determines the functional currency of each company in the Group. The functional currency is used to measure the financial condition and results of operations of each company separately . 2. Transactions, assets and liabilities in foreign currency: Transactions denominated in foreign currency are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated on each reporting date into the functional currency at the exchange rate at that date. Exchange rate differences are recognized in profit or loss. d. Convenience translation into U.S. dollars: The financial statements as of December 31, 2017 and for the year then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of December 31, 2017 (U.S. $1.00 = NIS 3.467). The translation was made solely for convenience purposes. The dollar amounts presented in these financial statements should not be construed as representing amounts that are receivable or payable in dollars or convertible into dollars, unless otherwise indicated. e. Cash equivalents: Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of acquisition. f. Restricted cash: Restricted cash is primarily invested to secure credit card payments and is used as security for the Company's lease commitment. g. Taxes on income: Tax results with respect to current or deferred taxes are recognized in profit or loss, unless they relate to items recognized in other comprehensive income or equity. 1. Current taxes The liability for current taxes is determined using the tax rates and tax laws that were enacted, or essentially enacted, by the reporting date, as well as adjustments required in connection with the taxes payable in respect of prior years. 2. Deferred taxes Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes. Deferred taxes are measured at the tax rate that is expected to apply when the asset is realized or the liability is settled, based on tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset is recognized to the extent that their utilization is probable. Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Company's policy not to initiate distribution of dividends from a subsidiary that would trigger an additional tax liability. Taxes on income that relate to distributions of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12. Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. h. Property, plant and equipment: Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Computers and Electronic Equipment 33 Laboratory and clinical experiments equipment 15 Leasehold improvements (* Office furniture and equipment 7 - 15 (* The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. An asset is derecognized upon disposal or when no further economic benefits are expected from its use. i. Research and development expenses, net of participations: Research and development expenses are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; The availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development. j. Government grants: Government grants received from the Israel-U.S. Binational Industrial Research and Development ("BIRD") Foundation are recognized upon receipt as a reduction in research and development expenses, as the Company evaluated that there is reasonable assurance that the Company will not be required to pay royalties, based on the best estimate of future sales using the original effective method. k. Impairment of non-financial assets: The Company evaluates the need to record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss. An impairment loss of an asset, other than goodwill, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount. The reversal of impairment loss of an asset presented at cost is recognized in profit or loss. m. Financial assets: Financial assets within the scope of Financial Instruments: Recognition and Measurement After initial recognition, the accounting treatment of financial assets is based on their classification as follows: Financial assets at fair value through profit or loss This category includes financial assets designated upon initial recognition at fair value through profit or loss. Loans and receivables Loans and receivables are investments with fixed or determinable payments that are not quoted in an active market. After initial recognition, loans are measured based on their terms at amortized cost plus directly attributable transaction costs using the effective interest method and less any impairment losses. Short-term borrowings are measured based on their terms, normally at face value. Financial liabilities: Financial liabilities within the scope of IAS 39 are initially measured at fair value. After initial recognition, other liabilities are measured according to their terms at amortized cost using the effective interest method, taking into account directly attributable transaction costs. The warrants were classified as a financial liability at fair value measured by quoted price and are marked to market through profit or loss in accordance with IAS 39. Issue of a unit of securities: The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit. n. Fair value measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. Fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - inputs other than quoted prices included within Level 1 that are observable directly or indirectly. Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). o. Treasury shares The Company's shares held by the Company are measured at their acquisition cost and are presented as an offset against the Company's equity. Any gain or loss deriving from the purchase, sale, issuance or cancellation of treasury shares is recognized directly in equity. p. Employee benefit liabilities: The Group has several employee benefit plans: 1. Short-term employment benefits: Short-term employee benefits are expected to be settled in full less than 12 months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. The liability for a cash bonus or profit-participating plan is recognized when the Company has a legal or constructive obligation to pay the said amount in respect of past services rendered by the employee and the amount may be reliably estimated. 2. Post-employment benefits: Post- The Company has defined contribution plans pursuant to Section 14 of the Israeli Severance Pay Law, into which the Company pays fixed contributions and has no legal or constructive obligation to pay further contributions on account of severance pay, even if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in current and prior periods. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services. q. Share-based payment transactions: From time to time the Company grants to its employees and other service providers remuneration in the form of equity-settled share-based instruments, such as options to purchase ordinary shares. Equity-settled transactions : The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model. As for other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured by reference to the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period in which the performance or service conditions are satisfied, and ending on the date on which the relevant employees become fully entitled to the award (the "Vesting Period"). No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied. When the Company changes the conditions of the award of equity-settled instruments, an additional expense is recognized beyond the original expense, calculated in respect of a change that increases the total fair value of the remuneration granted or benefits the other service provider according to the fair value on date of change. Cancellation of the award of equity-settled instruments is accounted for as having vested at the cancellation date and the expense not yet recognized in respect of the award is recognized immediately. However, if the cancelled grant is replaced by a new grant, and is intended as an alternate grant at the date awarded, the cancelled and new awards will both be accounted for as a change to the original award, as described above. r. Loss per share: Loss per share is calculated by dividing the net loss attributable to Company shareholders by the weighted number of outstanding ordinary shares during the period. Potential ordinary shares are only included in the computation of diluted loss per share when their conversion increases loss per share or decreases income per share. Potential ordinary shares that are converted during the period are included in diluted loss per share only until the conversion date and from that date in basic loss per share.

Significant Accounting Judgment

Significant Accounting Judgments, Estimates and Assumptions Used in Preparation of the Financial Statements	12 Months Ended
	Dec. 31, 2017
Significant Accounting Judgments, Estimates and Assumptions used in Preparation of the Financial Statements [Abstract]
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS	NOTE 3:- SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN PREPARATION OF THE FINANCIAL STATEMENTS Estimates and assumptions: The preparation of the Group's financial statements requires management to make estimates and assumptions that have an effect on application of the accounting policies and on the reported amounts of assets, liabilities and expenses. Changes in accounting estimates are The key assumptions made in the financial statements concerning uncertainties at the ● Determining the fair value of share-based transactions The fair value of share based transactions is determined upon initial recognition using acceptable option pricing models. The model is based on per-share price data and the exercise price and assumptions regarding expected volatility, expected life, expected dividend and risk-free interest rate.

Disclosure of New Standards in

Disclosure of New Standards in the Period Prior to their Adoption	12 Months Ended
	Dec. 31, 2017
Disclosure Of New Standards In The Period Prior To Their Adoption [Abstract]
DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION	NOTE 4:- DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION a. IFRS 15, "Revenue from Contracts with Customers": IFRS 15 was issued by the IASB in May 2014. IFRS 15 replaces IAS 18, "Revenue", IAS 11, "Construction Contracts", IFRIC 13, "Customer Loyalty Programs", IFRIC 15, "Agreements for the Construction of Real Estate", IFRIC 18, "Transfers of Assets from Customers" and SIC-31, "Revenue - Barter Transactions Involving Advertising Services". IFRS 15 introduces a five-step model that will apply to revenue earned from contracts with customers: Step 1: Identify the contract with a customer Step 2: Identify the separate performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the separate performance obligations Step 5: Recognize revenue when a performance obligation is satisfied, b. IFRS 9, "Financial Instruments": In July 2014, the IASB issued the final and complete version of IFRS 9, "Financial Instruments" ("IFRS 9"), which replaces IAS 39, "Financial Instruments: Recognition and Measurement". IFRS 9 mainly focuses on the classification and measurement of financial assets and it applies to all assets in the scope of IAS 39. According to IFRS 9, all financial assets are measured at fair value upon initial recognition. In subsequent periods, debt instruments are measured at amortized cost only if both of the following conditions are met: - The asset is held within a business model whose objective is to hold assets in order to collect the contractual cash flows. - the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. IFRS 9 also includes a new model for measurement of impairment of financial assets. Subsequent measurement of all other debt instruments and financial assets should be at fair value. IFRS 9 establishes a distinction between debt instruments to be measured at fair value through profit or loss and debt instruments to be measured at fair value through other comprehensive income. Financial assets that are equity instruments should be measured in subsequent periods at fair value and the changes recognized in profit or loss or in other comprehensive income (loss), in accordance with the election by the Company on an instrument-by-instrument basis. If equity instruments are held for trading, they should be measured at fair value through profit or loss. According to IFRS 9, the provisions of IAS 39 will continue to apply to derecognition and to financial liabilities for which the fair value option has not been elected. According to IFRS 9 The Company will adopt the new standard effective January 1, 2018. The Company does not expect the adoption IFRS 9 to have material impact on its financial statements. c. IFRS 16, "Leases": In January 2016, the IASB issued IFRS 16, "Leases". According to IFRS 16, a lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration. According to IFRS 16: ● Lessees are required to recognize an asset and a corresponding liability in the statement of financial position in respect of all leases (except in certain cases) similar to the accounting treatment of finance leases according to the existing IAS 17, "Leases". ● Lessees are required to initially recognize a lease liability for the obligation to make lease payments and a corresponding right-of-use asset. Lessees will also recognize interest and depreciation expenses separately. ● Variable lease payments that are not dependent on changes in the Consumer Price Index ("CPI") or interest rates, but are based on performance or use (such as a percentage of revenues) are recognized as an expense by the lessees as incurred and recognized as income by the lessors as earned. ● In the event of change in variable lease payments that are CPI-linked, lessees are required to remeasure the lease liability and the effect of the remeasurement is an adjustment to the carrying amount of the right-of-use asset. ● IFRS 16 includes two exceptions according to which lessees are permitted to elect to apply a method similar to the current accounting treatment for operating leases. These exceptions are leases for which the underlying asset is of low value and leases with a term of up to one year. ● The accounting treatment by lessors remains substantially unchanged, namely classification of a lease as a finance lease or an operating lease. For leases existing at the date of transition, IFRS 16 The Company is currently evaluating the impact of implementing this guidance on its consolidated financial statements. In 2018, the Company will continue to assess the potential effect of IFRS 16 on its consolidated financial statements as well as its adoption methodology.

Merger with Cellect Biotherapeu

Merger with Cellect Biotherapeutics Ltd. (Formerly "Cellect Biotechnology Ltd")	12 Months Ended
	Dec. 31, 2017
Merger with Cellect Biotherapeutics Ltd. (Formerly "Cellect Biotechnology Ltd") [Abstract]
MERGER WITH CELLECT BIOTHERAPEUTICS LTD. (formerly "Cellect Biotechnology Ltd")	NOTE 5:- MERGER WITH CELLECT BIOTHERAPEUTICS LTD. (formerly "Cellect Biotechnology Ltd") The merger between the Company and the Subsidiary, a private company engaged in development of innovative, unique technology, enabling selection of biologically filtered stem cells and commercialization, closed on July 1, 2013. Under the terms of the agreement, 44,887,373 ordinary shares, NIS 1.00 par value each, of the Company, constituting 85% of its equity, were issued to shareholders of the Subsidiary, as well as an aggregate of 568,395 options (not listed for trading), each exercisable for one ordinary share of the Company, NIS 1.00 par value each, in consideration for the entire share capital of the Subsidiary including all of the existing options in the Subsidiary, such that following the merger, the Subsidiary became a wholly-owned subsidiary of the Company. Out of the options granted, an amount of 113,698 Series 1 unlisted options are exercisable until April 30, 2018, at an exercise price of NIS 1.00 per option.

Marketable Securities Measured

Marketable Securities Measured at Fair Value through Profit and Loss	12 Months Ended
	Dec. 31, 2017
Marketable Securities Measured at Fair Value Through Profit and Loss [Abstract]
MARKETABLE SECURITIES MEASURED AT FAIR VALUE THROUGH PROFIT AND LOSS	NOTE 6:- MARKETABLE SECURITIES MEASURED AT FAIR VALUE THROUGH PROFIT AND LOSS Marketable securities are measured at fair value through profit and loss. As of December 31, 2017 and 2016, the marketable securities are comprised of NIS mutual funds that follow changes in short term Bank of Israel interest.

Other Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2017
Other Receivables [Abstract]
OTHER RECEIVABLES	NOTE 7:- OTHER RECEIVABLES Convenience translation December 31, December 31, 2016 2017 2017 N I S U.S. dollars Other receivables 51 60 17 Government authorities 611 185 54 Prepaid expenses 799 573 165 1,461 818 236

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 8:- PROPERTY, PLANT AND EQUIPMENT, NET Balance as of December 31, 2017: Laboratory equipment Leasehold improvements Office furniture and equipment Computers Total Cost Balance as of January 1, 2017 1,006 372 147 232 1,757 Additions during the year 244 12 24 65 345 Deductions during the year - - - (2 ) (2 ) Balance as of December 31, 2017 1,250 384 171 295 2,100 Accumulated Depreciation Balance as of January 1, 2017 140 116 18 110 384 Additions during the year: 162 125 13 72 372 Balance as of December 31, 2017 302 241 31 182 756 Depreciated cost as of December 31, 2017 948 143 140 113 1,344 Depreciated cost as of December 31, 2017 (convenience translation into U.S. dollars (Note 2d)) 274 41 40 33 388 Balance as of December 31, 2016: Laboratory equipment Leasehold improvements Vehicles Office furniture and equipment Computers Total Cost Balance as of January 1, 2016 687 244 176 36 149 1,292 Additions during the year: 319 128 - 111 83 641 Deductions during the year: - - (176 ) - - (176 ) Balance as of December 31, 2016 1,006 372 - 147 232 1,757 Accumulated Depreciation Balance as of January 1, 2016 12 - 37 8 48 105 Additions during the year: 128 116 25 10 62 341 Deductions during the year: - - (62 ) - - (62 ) Balance as of December 31, 2016 140 116 - 18 110 384 Depreciated cost as of December 31, 2016 866 256 - 129 122 1,373

Trade Payables

Trade Payables	12 Months Ended
	Dec. 31, 2017
Trade Payables/Other Payables [Abstract]
TRADE PAYABLES	NOTE 9:- TRADE PAYABLES Convenience translation December 31, December 31, 2016 2017 2017 N I S U.S. dollars Service providers 1,343 1,703 491 Notes payable 58 - - 1,401 1,703 491

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2017
Trade Payables/Other Payables [Abstract]
OTHER PAYABLES	NOTE 10:- OTHER PAYABLES Convenience translation December 31, December 31, 2016 2017 2017 N I S U.S. dollars Employees and payroll accruals *) 1,677 1,954 564 Accrued expenses 393 430 124 Other 14 12 3 2,084 2,396 691 *) Balance includes related parties (The Company's CEO and the Chairman of the Board of Directors).

Equity

Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
EQUITY	NOTE 11:- EQUITY a. Changes in share capital: Number of Shares Balance as of January 1, 2016 *) 75,994,888 Issuance of shares in private placement 5,783,437 Exercise of share options 4,000 Issuance of shares in an IPO 25,846,160 Balance as of December 31, 2016 *) 107,628,485 Issuance of shares in baby shelf offering 10,622,720 Exercise of share options 1,484,154 ADS granted (see Note 12c) 450,300 Balance as of December 31, 2017 *) 120,185,659 *) Net of 2,641,693 treasury shares of the Company, held by the Company. 1. On April 20, 2015, the Company published an offering under the shelf registration statement and prospectus dated November 25, 2014, pursuant to which the public was offered up to 4,500,000 shares and up to 4,500,000 options (Series 1), exercisable into 4,500,000 ordinary shares of the Company. The Company exercised its right for an over-allotment not to exceed 15% of the total securities offered through the offering, such that in total, the Company issued 4,523,500 ordinary shares and 4,523,500 options (Series 1) of the Company. The total gross proceeds received by the Company in respect of the securities offered to the public according to the shelf offering totaled NIS 6,604 (proceeds net of issuance costs amounted to NIS 6,292). 2. During June 2015, 341,073 unlisted options were exercised for 341,073 shares of the Company, in consideration for a total of NIS 104. 3. In February 2016, the Company completed a private placement of shares and warrants for a total of approximately NIS 8,000 and issued 5,783,437 ordinary shares as well as 1,927,801 unlisted warrants exercisable for a period of 12 months, at an exercise price of NIS 2.1 per warrant. Participants in the private placement also included related parties and an officer of the Company. On May 16, 2016 the Company’s shareholders, at a general meeting approved the participation of the controlling shareholder and Chairman of the Board, Nuriel Kasbian Chirich, in the private placement, and accordingly he was allotted 287,769 shares and 95,923 unlisted warrants of the Company on the same terms as the rest of the offerees. On January 9, 2017, the Company’s shareholders, at general meeting of the Company's shareholders approved the extension of the exercise period of the warrants until March 7, 2018. 4. On July 28, 2016 the Company completed a US initial public offering (the “IPO”) of 1,292,308 ADSs and listed warrants to purchase 969,231 ADSs (the “Listed Warrants”) at a combined price to the public of $6.50 resulting in Each Listed Warrants is exercisable into one ADS, for a period of five years at an exercise price of US$ 7.50 per warrant. Since the warrant exercise price is in US dollars, which is not the Company's functional currency, the Listed Warrants were classified as a financial liability at fair value and are marked to market through profit or loss in accordance with IAS 39. The Company granted the underwriters a 45-day over-allotment to purchase up to 193,846 additional ADSs at a price of US$ 6.038 per ADS and/or an additional Listed Warrants to purchase 145,385 ADSs, on the same terms as the warrants issued to the public, at a price of US$ 0.007 per warrant. The underwriters partially exercised the over-allotment option resulting in the issuance of 65,890 Listed Warrants. The option to the Underwriters was recognized as a share based payment transaction in accordance with IFRS 2, and was netted off the total consideration as issuance cost. Furthermore, the Company issued to the underwriters unlisted warrants to purchase 77,538 ADSs at an exercise price of $8.80 per warrant convertible at a 1:1 ratio and exercisable for a period of four years. The underwriters' unlisted warrants were classified as a share based payment transaction in accordance with IFRS 2 and netted off the total consideration as issuance cost 5. On May 9, 2017, the Company's shareholders, at a general shareholders' meeting approved the following changes in the terms of the options (Series 1): (i) extension of the expiration date options (Series 1) to a date that is 80 days from court approval for such Section 350 of the Israeli Companies Law. On May 29, 2017, the court approved the changes to the options (Series 1). 6. Between July 1, 2017, and August 16, 2017, an aggregate of 516,574 options (Series 1) were exercised. Each option (Series 1) was exercised into one ordinary share at an exercise price of NIS 1.20 per option. 7. On September 7, 2017, the Company sold to certain accredited investors an aggregate of 531,136 ADSs and 265,568 unregistered warrants to purchase 265,568 ADSs in a registered direct offering at $8.10 per ADS in which it raised gross proceeds of NIS 15,214, (NIS 13,970 net of all issuance costs, including share-based awards granted). An amount of NIS 11,695 out of the consideration related to the ADSs and classified as equity component, while an amount of NIS 2,481 related to the fair value of the warrants to purchase ADSs and was classified as a liability. Issuance costs amounting to NIS 204 associated with the issuance of the warrants, have been recognized as finance expenses. The investor warrants may be exercised for one year from issuance and have an exercise price of $12.07 per ADS, subject to adjustment as set forth therein. The investor warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants. The Company paid approximately $140 in placement agent fees and expenses and issued unregistered placement agent warrants to purchase 7,492 ADSs on the same general terms as the investor warrants except they have an exercise price of $10.125 per ADS. Since the warrant exercise price is in US dollars, which is not the Company's functional currency, the unregistered warrants to purchase ADS were classified as a financial liability at fair value and are marked to market through profit or loss in accordance with IAS 39. The placement agent warrants were classified as a share based payment transaction in accordance with IFRS 2 and netted off the total consideration as issuance cost. b. Rights related to ordinary shares All ordinary shares shall have equal rights and each ordinary share shall entitle the holder the following rights: 1. The right to receive notices of any general meeting of shareholders, to participate in meetings and vote on any matter raised in the meeting. Each ordinary share entitles its holder to one vote. 2. The right to participate in any distribution by the Company to its shareholders and receive dividends and / or bonus shares, if distributed in accordance with the Company articles of association. 3. The right to participate at the time of liquidation of the Company, in the distribution of the Company's assets permitted to be distributed in proportion to the number of shares allocated and the degree of repayment by the shareholders, if not fully paid, and subject to the provisions of the articles of association of the Company and without prejudice to existing rights of shareholders of any kind.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2017
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	NOTE 12:- SHARE-BASED COMPENSATION a. In February 2014, the Company's board of directors adopted an Employee Shares Incentive Plan (the "2014 Plan"). Under the 2014 Plan, options may be granted to employees, officers, directors, consultants, advisers and service providers of the Company. On February 28, 2017, the board of directors approved an increase to the Company’s option pool of 4,207,971 options. As a result, the Company has a total of 12,707,971 options in the pool. b. On November 23, 2015, the Company's shareholders, at a general meeting of shareholders approved the former Deputy CEO and CFO terms of service, including a grant of options, which is an exception from the Company's compensation policy, as further described below. The terms of service included among others, a grant of 2,658,246 options, exercisable for 2,658,246 ordinary shares, no par value, of the Company at an exercise price of NIS 1.286 per share. The total benefit in respect of the grant calculated at the grant date was NIS 3,033. On March 28, 2017, 500,000 options were exercised into 500,000 ordinary shares by the Company’s former Deputy CEO and CFO. During January, 2018, 310,180 options were exercised into 310,180 ordinary shares by the Company’s former Deputy CEO and CFO. The remaining 297,420 options expired on February 28, 2018. c. Details on share-based payment for service providers: 1. On February 28, 2017, the board of directors approved the issuance to a consultant of 15,000 ADSs. The issuance was made in three equal tranches, of 5,000 ADSs each. The first tranche was issued in May 2017, the second tranche was issued in July 2017 and the third tranche was issued in November 2017. 2. On July 23, 2017, the Company issued 7,515 ADSs to a consultant. On June 28, 2017, the board of directors approved the issuance of ADSs. d. Expense recognized in the financial statements: The expense that was recognized for services received from employees, directors and service providers is as follows: Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 N I S U.S. dollars Research and development 523 253 1,940 560 General and administrative 795 1,299 3,444 993 Total share-based compensation 1,318 1,552 5,384 1,553 e. Activity during the year: The table below includes the number of share options, and the weighted average of their exercise prices: 2016 2017 Number of options Weighted Average Exercise price Number of options Weighted Average Exercise price NIS NIS Outstanding at beginning of year 5,764,866 1.37 5,979,973 1.25 Options exercised for shares - - (696,980 ) 1.16 Options forfeited (2,054,396 ) 1.43 (166,667 ) 0.63 Option Expired (337,000 ) 1.42 (726,512 ) 1.69 Granted 2,606,503 1.14 6,362,854 1.16 Outstanding at end of year 5,979,973 1.25 10,752,668 1.18 f. The following table summarizes information about the Company's outstanding and exercisable options granted to employees and consultants as of December 31, 2017: Exercise price (Range) Options outstanding as of December 31, 2017 Weighted average remaining contractual term (years) Options exercisable as of December 31, 2017 Weighted average remaining contractual term (years) 0.001 - 1.35 8,310,168 8.3 1,452,782 4.3 1.35 - 1.8 2,010,500 7.7 1,335,000 6.7 1.8 - 2.1 432,000 7.6 432,000 7.6 10,752,668 8.2 3,219,782 5.8 g. Measuring the fair value of share options settled by equity instruments: The Company shares data which is useful for measuring the fair value of the options under the Black-Scholes model, for the years ended December 31, 2016 and 2017, is as follows: 2016 2017 Dividend yield (%) 0 0 Expected volatility of the share prices (%) 84.05%-91.6% 81.56%-85.61% Risk-free interest rate (%) 1.04%-2.10% 1.94%-2.52% Expected life of share options (years) 4-10 10 According to the data above, the fair value of options granted in the years 2016-2017 was set to NIS 10, 252 at the grant date. h. The determination of the grant date fair value of options using an option pricing model (the Company utilizes the Black-Scholes model) is affected by estimates and assumptions regarding a number of complex and subjective variables. These variables include the expected volatility of the Company's share price over the expected term of the options, share option exercise and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as follows: 1. The expected share price volatility is based on the historical volatility in the trading price of the Company's ordinary shares as well as comparable companies on the TASE and on the NASDAQ and benchmarks of related companies. 2. The expected term of options granted is based upon the contractual life of the options and represents the period of time that options granted are expected to be outstanding. 3. The risk-free interest rate is based on the yield from Israeli government bonds with a term equivalent to the contractual life of the options. 4. The Company has never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2017
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 13:- TAXES ON INCOME a. Corporate tax rates in Israel: The Israeli corporate income tax rate was 24% in 2017, 25% in 2016 and 26.5% in 2015. In January 2016, the Law for Amending the Income Tax Ordinance (No. 216) (Reduction of Corporate Tax Rate), 2016 was approved, which includes a reduction of the corporate tax rate from 26.5% to 25%, effective from January 1, 2016. In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018. b. Final tax assessments: The Company and its subsidiary received final tax assessments through tax years 2012. c. Net operating carry forwards losses for tax purposes and other temporary differences: As of December 31, 2017, the Company had carry forward operating losses amounting to approximately NIS 35,085. The Company did not recognize deferred tax assets for carry forward operating and capital losses and other temporary differences because their utilization in the foreseeable future is not probable.

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	12 Months Ended
	Dec. 31, 2017
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	NOTE 14:- CONTINGENT LIABILITIES AND COMMITMENTS a. Commitments 1. On September 1, 2015, the Company signed a new lease agreement for new offices. The aforementioned lease agreement is for a minimum period of 3 years from the date of signing the agreement. Under this agreement, the Company will pay a monthly rental fee plus an administration fee of NIS 34. The Company has entered into operating lease agreements for vehicles. These leases have an average life of three years with no option to extend the contract. The Company has the right to terminate the agreement before the end of the three years and will be required to pay an early termination penalty of between one to three months of the lease. The future lease payments as of December 31, 2017 are approximately NIS 183. 2. The Company participated in programs sponsored by the Israel-United States Binational Industrial Research and Development Foundation (BIRD) for the support of research and development activities. The Company is obligated to pay royalties to BIRD, amounting to 5% of the gross sales of the products and other related revenues developed from such activities, up to an amount of 150% from the grant received from BIRD by the Company indexed to the U.S. consumer price index. As of December 31, 2017, the Company received an aggregate grant of $120 from the BIRD Foundation in support of the development and commercialization of the Company's stem cell selection technology in collaboration with Entegris. Subject to the successful completion of different milestones, the Company expects to receive additional grants in the future. b. Liens: The Company provided a NIS 185 restricted bank deposit to secure credit card payments. The Company provided a NIS 120 restricted bank deposit to secure the rent payment.

Balances and Transactions with

Balances and Transactions with Related Parties	12 Months Ended
	Dec. 31, 2017
Balances and Transactions with Related Parties [Abstract]
BALANCES AND TRANSACTIONS WITH RELATED PARTIES	NOTE 15: - BALANCES AND TRANSACTIONS WITH RELATED PARTIES a. Related party balances Convenience translation (Note 2d) December 31 Year ended December 31, 2016 2017 2017 Key management personnel Other related parties Key management personnel Other related parties Key management personnel Other related parties NIS U.S. Dollars Other payables 318 805 425 827 123 238 318 805 425 827 123 238 b. The directors and senior managers of the Company are entitled, in addition to salary, to non-cash benefits (such as a car, medical insurance, etc.). Benefits for employment of key management personnel (including directors) employed in the Company: Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 No. of people Amount NIS No. of people Amount NIS No. of people Amount NIS Amount U.S. dollars Short-term employee benefits (includes Company's CEO in 2015, 2016 and 2017) 5 3,423 7 6,040 5 7,816 2,254 c. Benefits for employment of key management personnel (including directors) that are not employed in the Company: Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 No. of people Amount NIS No. of people Amount NIS No. of people Amount NIS Amount U.S. dollars Key management personnel and related parties 2 444 - - - - - Directors' fees 5 477 5 513 8 682 197 7 921 5 513 8 682 197 d. Transactions with related parties: Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 Key management personnel Related parties Key management personnel Related parties Key management personnel Related parties Key management personnel Related parties Research and development expenses 713 1,422 1,063 1,544 634 2,661 183 767 General and administrative expenses 921 811 2,317 1,116 2,014 2,507 581 724 1,634 2,233 3,380 2,660 2,648 5,168 764 1,491

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16: SUBSEQUENT EVENTS On January 29, 2018, the Company sold to certain accredited investors an aggregate of 484,848 ADSs in a registered direct offering at $8.25 per ADS resulting in proceeds of approximately NIS 12,500 ($3,600) net of issuance costs. In addition, the Company issued to the investors unregistered warrants to purchase 266,667 ADSs in a private placement. The investor warrants may be exercised until February 7, 2019 and have an exercise price of $12.00 per ADS, subject to adjustment as set forth therein. The investor warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants. The Company paid approximately $305 in placement agent fees and expenses and issued unregistered placement agent warrants to purchase 24,242 ADS on the same general terms as the investor warrants except they have an exercise price of $10.31 per ADS.

Significant Accounting Polici23

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Significant Accounting Policies [Abstract]
Basis of presentation of the financial statements:	a. Basis of presentation of the financial statements: These financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"). The Company's financial statements have been prepared on a cost basis, except for marketable securities and liability related to warrants that are measured at fair value through profit or loss. The Company has elected to present profit or loss items using the "function of expense" method. The Company's operating cycle is one year.
Consolidated financial statements:	b. Consolidated financial statements: The consolidated financial statements include the financial statements of companies that the Company controls (subsidiaries). Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases. The financial statements of the Company and its subsidiaries (the "Group") are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intercompany balances and transactions and gains or losses resulting from intragroup transactions are eliminated in full in the consolidated financial statements.
Functional currency, reporting currency and foreign currency:	c. Functional currency, reporting currency and foreign currency: 1. Functional currency and reporting currency: The reporting and the functional currency of the Company is the New Israeli Shekel (“NIS”). The Company determines the functional currency of each company in the Group. The functional currency is used to measure the financial condition and results of operations of each company separately . 2. Transactions, assets and liabilities in foreign currency: Transactions denominated in foreign currency are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated on each reporting date into the functional currency at the exchange rate at that date. Exchange rate differences are recognized in profit or loss.
Convenience translation into U.S. dollars:	d. Convenience translation into U.S. dollars: The financial statements as of December 31, 2017 and for the year then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of December 31, 2017 (U.S. $1.00 = NIS 3.467). The translation was made solely for convenience purposes. The dollar amounts presented in these financial statements should not be construed as representing amounts that are receivable or payable in dollars or convertible into dollars, unless otherwise indicated.
Cash equivalents:	e. Cash equivalents: Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of acquisition.
Restricted cash:	f. Restricted cash: Restricted cash is primarily invested to secure credit card payments and is used as security for the Company's lease commitment.
Taxes on income:	g. Taxes on income: Tax results with respect to current or deferred taxes are recognized in profit or loss, unless they relate to items recognized in other comprehensive income or equity.
Current taxes	1. Current taxes The liability for current taxes is determined using the tax rates and tax laws that were enacted, or essentially enacted, by the reporting date, as well as adjustments required in connection with the taxes payable in respect of prior years.
Deferred taxes	2. Deferred taxes Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes. Deferred taxes are measured at the tax rate that is expected to apply when the asset is realized or the liability is settled, based on tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset is recognized to the extent that their utilization is probable. Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Company's policy not to initiate distribution of dividends from a subsidiary that would trigger an additional tax liability. Taxes on income that relate to distributions of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12. Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority.
Property, plant and equipment:	h. Property, plant and equipment: Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Computers and Electronic Equipment 33 Laboratory and clinical experiments equipment 15 Leasehold improvements (* Office furniture and equipment 7 - 15 (* The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. An asset is derecognized upon disposal or when no further economic benefits are expected from its use.
Research and development expenses, net of participations:	i. Research and development expenses, net of participations: Research and development expenses are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company's intention to complete the intangible asset and use or sell it; the Company's ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; The availability of adequate technical, financial and other resources to complete the intangible asset; and the Company's ability to measure reliably the expenditure attributable to the intangible asset during its development.
Government grants:	j. Government grants: Government grants received from the Israel-U.S. Binational Industrial Research and Development ("BIRD") Foundation are recognized upon receipt as a reduction in research and development expenses, as the Company evaluated that there is reasonable assurance that the Company will not be required to pay royalties, based on the best estimate of future sales using the original effective method.
Impairment of non-financial assets:	k. Impairment of non-financial assets: The Company evaluates the need to record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss. An impairment loss of an asset, other than goodwill, is reversed only if there have been changes in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years and its recoverable amount. The reversal of impairment loss of an asset presented at cost is recognized in profit or loss.
Financial assets:	m. Financial assets: Financial assets within the scope of Financial Instruments: Recognition and Measurement After initial recognition, the accounting treatment of financial assets is based on their classification as follows: Financial assets at fair value through profit or loss This category includes financial assets designated upon initial recognition at fair value through profit or loss. Loans and receivables Loans and receivables are investments with fixed or determinable payments that are not quoted in an active market. After initial recognition, loans are measured based on their terms at amortized cost plus directly attributable transaction costs using the effective interest method and less any impairment losses. Short-term borrowings are measured based on their terms, normally at face value. Financial liabilities: Financial liabilities within the scope of IAS 39 are initially measured at fair value. After initial recognition, other liabilities are measured according to their terms at amortized cost using the effective interest method, taking into account directly attributable transaction costs. The warrants were classified as a financial liability at fair value measured by quoted price and are marked to market through profit or loss in accordance with IAS 39. Issue of a unit of securities: The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.
Fair value measurement	n. Fair value measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurement is based on the assumption that the transaction will take place in the asset's or the liability's principal market, or in the absence of a principal market, in the most advantageous market. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. Fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - inputs other than quoted prices included within Level 1 that are observable directly or indirectly. Level 3 - inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
Treasury shares	o. Treasury shares The Company's shares held by the Company are measured at their acquisition cost and are presented as an offset against the Company's equity. Any gain or loss deriving from the purchase, sale, issuance or cancellation of treasury shares is recognized directly in equity.
Employee benefit liabilities:	p. Employee benefit liabilities: The Group has several employee benefit plans: 1. Short-term employment benefits: Short-term employee benefits are expected to be settled in full less than 12 months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. The liability for a cash bonus or profit-participating plan is recognized when the Company has a legal or constructive obligation to pay the said amount in respect of past services rendered by the employee and the amount may be reliably estimated. 2. Post-employment benefits: Post- The Company has defined contribution plans pursuant to Section 14 of the Israeli Severance Pay Law, into which the Company pays fixed contributions and has no legal or constructive obligation to pay further contributions on account of severance pay, even if the fund does not hold sufficient amounts to pay all employee benefits relating to employee service in current and prior periods. Contributions to the defined contribution plan in respect of severance or retirement pay are recognized as an expense when contributed concurrently with performance of the employee's services.
Share-based payment transactions:	q. Share-based payment transactions: From time to time the Company grants to its employees and other service providers remuneration in the form of equity-settled share-based instruments, such as options to purchase ordinary shares. Equity-settled transactions : The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model. As for other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured by reference to the fair value of the equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period in which the performance or service conditions are satisfied, and ending on the date on which the relevant employees become fully entitled to the award (the "Vesting Period"). No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied. When the Company changes the conditions of the award of equity-settled instruments, an additional expense is recognized beyond the original expense, calculated in respect of a change that increases the total fair value of the remuneration granted or benefits the other service provider according to the fair value on date of change. Cancellation of the award of equity-settled instruments is accounted for as having vested at the cancellation date and the expense not yet recognized in respect of the award is recognized immediately. However, if the cancelled grant is replaced by a new grant, and is intended as an alternate grant at the date awarded, the cancelled and new awards will both be accounted for as a change to the original award, as described above.
Loss per share:	r. Loss per share: Loss per share is calculated by dividing the net loss attributable to Company shareholders by the weighted number of outstanding ordinary shares during the period. Potential ordinary shares are only included in the computation of diluted loss per share when their conversion increases loss per share or decreases income per share. Potential ordinary shares that are converted during the period are included in diluted loss per share only until the conversion date and from that date in basic loss per share.

Significant Accounting Polici24

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Significant Accounting Policies [Abstract]
Summary of straight-line basis over the useful life of the assets at annual rates	% Computers and Electronic Equipment 33 Laboratory and clinical experiments equipment 15 Leasehold improvements (* Office furniture and equipment 7 - 15 (*

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2017
Other Receivables [Abstract]
Schedule of other receivables	Convenience translation December 31, December 31, 2016 2017 2017 N I S U.S. dollars Other receivables 51 60 17 Government authorities 611 185 54 Prepaid expenses 799 573 165 1,461 818 236

Property, Plant and Equipment26

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Schedule of property, plant and equipment, net	Balance as of December 31, 2017: Laboratory equipment Leasehold improvements Office furniture and equipment Computers Total Cost Balance as of January 1, 2017 1,006 372 147 232 1,757 Additions during the year 244 12 24 65 345 Deductions during the year - - - (2 ) (2 ) Balance as of December 31, 2017 1,250 384 171 295 2,100 Accumulated Depreciation Balance as of January 1, 2017 140 116 18 110 384 Additions during the year: 162 125 13 72 372 Balance as of December 31, 2017 302 241 31 182 756 Depreciated cost as of December 31, 2017 948 143 140 113 1,344 Depreciated cost as of December 31, 2017 (convenience translation into U.S. dollars (Note 2d)) 274 41 40 33 388 Balance as of December 31, 2016: Laboratory equipment Leasehold improvements Vehicles Office furniture and equipment Computers Total Cost Balance as of January 1, 2016 687 244 176 36 149 1,292 Additions during the year: 319 128 - 111 83 641 Deductions during the year: - - (176 ) - - (176 ) Balance as of December 31, 2016 1,006 372 - 147 232 1,757 Accumulated Depreciation Balance as of January 1, 2016 12 - 37 8 48 105 Additions during the year: 128 116 25 10 62 341 Deductions during the year: - - (62 ) - - (62 ) Balance as of December 31, 2016 140 116 - 18 110 384 Depreciated cost as of December 31, 2016 866 256 - 129 122 1,373

Trade Payables (Tables)

Trade Payables (Tables)	12 Months Ended
	Dec. 31, 2017
Trade Payables/Other Payables [Abstract]
Schedule of trade payables	Convenience translation December 31, December 31, 2016 2017 2017 N I S U.S. dollars Service providers 1,343 1,703 491 Notes payable 58 - - 1,401 1,703 491

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2017
Trade Payables/Other Payables [Abstract]
Schedule of other payables	Convenience translation December 31, December 31, 2016 2017 2017 N I S U.S. dollars Employees and payroll accruals *) 1,677 1,954 564 Accrued expenses 393 430 124 Other 14 12 3 2,084 2,396 691 *) Balance includes related parties (The Company's CEO and the Chairman of the Board of Directors).

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of changes in share capital	Number of Shares Balance as of January 1, 2016 *) 75,994,888 Issuance of shares in private placement 5,783,437 Exercise of share options 4,000 Issuance of shares in an IPO 25,846,160 Balance as of December 31, 2016 *) 107,628,485 Issuance of shares in baby shelf offering 10,622,720 Exercise of share options 1,484,154 ADS granted (see Note 12c) 450,300 Balance as of December 31, 2017 *) 120,185,659 *) Net of 2,641,693 treasury shares of the Company, held by the Company.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Share-Based Compensation [Abstract]
Schedule of services received from employees, directors and service providers	Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 N I S U.S. dollars Research and development 523 253 1,940 560 General and administrative 795 1,299 3,444 993 Total share-based compensation 1,318 1,552 5,384 1,553
Schedule of number of share options and weighted average exercise prices	2016 2017 Number of options Weighted Average Exercise price Number of options Weighted Average Exercise price NIS NIS Outstanding at beginning of year 5,764,866 1.37 5,979,973 1.25 Options exercised for shares - - (696,980 ) 1.16 Options forfeited (2,054,396 ) 1.43 (166,667 ) 0.63 Option Expired (337,000 ) 1.42 (726,512 ) 1.69 Granted 2,606,503 1.14 6,362,854 1.16 Outstanding at end of year 5,979,973 1.25 10,752,668 1.18
Schedule of outstanding and exercisable options granted to employees and consultants	Exercise price (Range) Options outstanding as of December 31, 2017 Weighted average remaining contractual term (years) Options exercisable as of December 31, 2017 Weighted average remaining contractual term (years) 0.001 - 1.35 8,310,168 8.3 1,452,782 4.3 1.35 - 1.8 2,010,500 7.7 1,335,000 6.7 1.8 - 2.1 432,000 7.6 432,000 7.6 10,752,668 8.2 3,219,782 5.8
Schedule of fair value of options under black-scholes	2016 2017 Dividend yield (%) 0 0 Expected volatility of the share prices (%) 84.05%-91.6% 81.56%-85.61% Risk-free interest rate (%) 1.04%-2.10% 1.94%-2.52% Expected life of share options (years) 4-10 10

Balances and Transactions wit31

Balances and Transactions with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Balances and Transactions with Related Parties [Abstract]
Schedule of related party balances	Convenience translation (Note 2d) December 31 Year ended December 31, 2016 2017 2017 Key management personnel Other related parties Key management personnel Other related parties Key management personnel Other related parties NIS U.S. Dollars Other payables 318 805 425 827 123 238 318 805 425 827 123 238
Schedule of benefits for employment of key management personnel (including directors) employed	Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 No. of people Amount NIS No. of people Amount NIS No. of people Amount NIS Amount U.S. dollars Short-term employee benefits (includes Company's CEO in 2015, 2016 and 2017) 5 3,423 7 6,040 5 7,816 2,254
Schedule of benefits for employment of key management personnel (including directors) not employed	Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 No. of people Amount NIS No. of people Amount NIS No. of people Amount NIS Amount U.S. dollars Key management personnel and related parties 2 444 - - - - - Directors' fees 5 477 5 513 8 682 197 7 921 5 513 8 682 197
Schedule of transactions with related parties	Convenience translation (Note 2d) Year ended December 31, Year ended December 31, 2015 2016 2017 2017 Key management personnel Related parties Key management personnel Related parties Key management personnel Related parties Key management personnel Related parties Research and development expenses 713 1,422 1,063 1,544 634 2,661 183 767 General and administrative expenses 921 811 2,317 1,116 2,014 2,507 581 724 1,634 2,233 3,380 2,660 2,648 5,168 764 1,491

General (Details)

General (Details) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)	Dec. 31, 2015ILS (₪)	Dec. 31, 2017USD ($)
General (Textual)
Net loss	₪ (28,224)	$ (8,141)	₪ (15,317)	₪ (10,172)
Negative cash flows from operating activities	(17,770)	$ (5,126)	(14,412)	₪ (7,710)
Accumulated deficit	₪ (63,943)		₪ (35,719)		$ (18,444)

Significant Accounting Polici33

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2017
Computers and Electronic Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, depreciation annual rates	33
Laboratory and clinical experiments equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, depreciation annual rates	15
Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, depreciation annual rates	0	[1]
Office furniture and equipment [Member] | Bottom of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, depreciation annual rates	7
Office furniture and equipment [Member] | Top of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment, depreciation annual rates	15
[1]	Leasehold improvements are depreciated on a straight-line basis over the earlier of the lease term or the estimated useful life of the improvement.

Significant Accounting Polici34

Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2017
Significant Accounting Policies (Textual)
Description of translated exchange rate	The financial statements as of December 31, 2017 and for the year then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of December 31, 2017 (U.S. $1.00 = NIS 3.467).

Merger with Cellect Biotherap35

Merger with Cellect Biotherapeutics Ltd. (Formerly "Cellect Biotechnology Ltd") (Details) - ₪ / shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Merger with Cellect Biotherapeutics Ltd. (formerly "Cellect Biotechnology Ltd") (Textual)
Number of shares issued	[1]	120,140,659	107,583,485
Par value per share
Ordinary shares [Member]
Merger with Cellect Biotherapeutics Ltd. (formerly "Cellect Biotechnology Ltd") (Textual)
Number of shares issued		44,887,373
Par value per share		₪ 1
Equity interest, percentage		85.00%
Not listed for trading [Member]
Merger with Cellect Biotherapeutics Ltd. (formerly "Cellect Biotechnology Ltd") (Textual)
Number of options issued		568,395
Exercise price, per option		₪ 1
Series 1 unlisted options [Member]
Merger with Cellect Biotherapeutics Ltd. (formerly "Cellect Biotechnology Ltd") (Textual)
Number of options issued		113,698
Exercise price, per option		₪ 1
[1]	Net of 2,641,693 treasury shares of the Company, held by the Company.

Other Receivables (Details)

Other Receivables (Details) ₪ in Thousands, $ in Thousands	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)
Other Receivables [Abstract]
Other receivables	₪ 60	$ 17	₪ 51
Government authorities	185	54	611
Prepaid expenses	573	165	799
Total other receivables	₪ 818	$ 236	₪ 1,461

Property, Plant and Equipment37

Property, Plant and Equipment, Net (Details) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)
Disclosure of detailed information about property, plant and equipment [line items]
Cost, Beginning Balance	₪ 1,373		₪ 1,292
Cost, Additions during the year	345		641
Cost, Deductions during the year	(2)		(176)
Cost, Ending Balance	1,344	$ 388	1,373
Accumulated Depreciation, Beginning Balance	384		105
Accumulated Depreciation, Additions during the year:	372		341
Accumulated Depreciation, Deductions during the year			(62)
Accumulated Depreciation, Ending Balance	756		384
Depreciated cost	1,344		1,373
Depreciated cost (convenience translation into U.S. dollars (Note 2d)) | $		388
Laboratory equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Cost, Beginning Balance	1,006		687
Cost, Additions during the year	244		319
Cost, Deductions during the year
Cost, Ending Balance	1,250		1,006
Accumulated Depreciation, Beginning Balance	140		12
Accumulated Depreciation, Additions during the year:	162		128
Accumulated Depreciation, Deductions during the year
Accumulated Depreciation, Ending Balance	302		140
Depreciated cost	948		866
Depreciated cost (convenience translation into U.S. dollars (Note 2d)) | $		274
Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Cost, Beginning Balance	372		244
Cost, Additions during the year	12		128
Cost, Deductions during the year
Cost, Ending Balance	384		372
Accumulated Depreciation, Beginning Balance	116
Accumulated Depreciation, Additions during the year:	125		116
Accumulated Depreciation, Deductions during the year
Accumulated Depreciation, Ending Balance	241		116
Depreciated cost	143		256
Depreciated cost (convenience translation into U.S. dollars (Note 2d)) | $		41
Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Cost, Beginning Balance			176
Cost, Additions during the year
Cost, Deductions during the year			(176)
Cost, Ending Balance
Accumulated Depreciation, Beginning Balance			37
Accumulated Depreciation, Additions during the year:			25
Accumulated Depreciation, Deductions during the year			(62)
Accumulated Depreciation, Ending Balance
Depreciated cost
Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Cost, Beginning Balance	147		36
Cost, Additions during the year	24		111
Cost, Deductions during the year
Cost, Ending Balance	171		147
Accumulated Depreciation, Beginning Balance	18		8
Accumulated Depreciation, Additions during the year:	13		10
Accumulated Depreciation, Deductions during the year
Accumulated Depreciation, Ending Balance	31		18
Depreciated cost	140		129
Depreciated cost (convenience translation into U.S. dollars (Note 2d)) | $		40
Computers [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Cost, Beginning Balance	232		149
Cost, Additions during the year	65		83
Cost, Deductions during the year	(2)
Cost, Ending Balance	295		232
Accumulated Depreciation, Beginning Balance	110		48
Accumulated Depreciation, Additions during the year:	72		62
Accumulated Depreciation, Deductions during the year
Accumulated Depreciation, Ending Balance	182		110
Depreciated cost	₪ 113		₪ 122
Depreciated cost (convenience translation into U.S. dollars (Note 2d)) | $		$ 33

Trade Payables (Details)

Trade Payables (Details) ₪ in Thousands, $ in Thousands	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)
Trade Payables/Other Payables [Abstract]
Service providers	₪ 1,703	$ 491	₪ 1,343
Notes payable			58
Trade payables, Total	₪ 1,703	$ 491	₪ 1,401

Other Payables (Details)

Other Payables (Details) ₪ in Thousands, $ in Thousands		Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)
Trade Payables/Other Payables [Abstract]
Employees and payroll accruals	[1]	₪ 1,954	$ 564	₪ 1,677
Accrued expenses		430	124	393
Other		12	3	14
Other payables		₪ 2,396	$ 691	₪ 2,084
[1]	Balance includes related parties (The Company's CEO and the Chairman of the Board of Directors).

Equity (Details)

Equity (Details) - shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Number of Shares (issued and outstanding)
Balance	[1]	107,628,485	75,994,888
Issuance of shares in baby shelf offering		10,622,720
Issuance of shares in private placement			5,783,437
Exercise of share options		1,484,154	4,000
ADS granted (see Note 12c)		450,300
Issuance of shares in an IPO			25,846,160
Balance	[1]	120,185,659	107,628,485
[1]	Net of 2,641,693 treasury shares of the Company, held by the Company.

Equity (Details Textual)

Equity (Details Textual) ₪ / shares in Units, $ / shares in Units, ₪ in Thousands, $ in Thousands

Sep. 07, 2017ILS (₪)shares

Sep. 07, 2017USD ($)$ / sharesshares

May 09, 2017

Apr. 04, 2017shares

Jul. 28, 2016ILS (₪)Shareshares

Jul. 28, 2016ILS (₪)Share$ / shares

May 16, 2016shares

Feb. 28, 2016ILS (₪)shares

Feb. 28, 2016$ / shares

Jun. 30, 2015ILS (₪)shares

Apr. 20, 2015ILS (₪)

Aug. 16, 2017₪ / sharesshares

Dec. 31, 2017ILS (₪)shares

Dec. 31, 2017USD ($)shares

Dec. 31, 2016ILS (₪)

Dec. 31, 2015ILS (₪)

Equity (Textual)

Proceeds net of issuance costs | ₪

₪ 11,695

₪ 6,292

Net of treasury shares

2,686,693

2,686,693

Number of ordinary shares

1

Issuance of share

516,574

Published offering, description

The Company published an offering under the shelf registration statement and prospectus dated November 25, 2014, pursuant to which the public was offered up to 4,500,000 shares and up to 4,500,000 options (Series 1), exercisable into 4,500,000 ordinary shares of the Company. The Company exercised its right for an over-allotment not to exceed 15% of the total securities offered through the offering, such that in total, the Company issued 4,523,500 ordinary shares and 4,523,500 options (Series 1) of the Company.

Gross proceeds from sale of security | ₪

₪ 6,604

Options exercised

341,073

Exercise of share options and warrants | ₪

₪ 104

₪ 1,432

₪ 7

₪ 104

Private placement of shares and warrants | ₪

₪ 8,000

Unlisted warrants exercisable

1,927,801

Warrants exercisable term

12 months

Private placement allotted shares

287,769

Gross proceeds | ₪

15,214

₪ 32,107

Unlisted warrants

95,923

Issuance costs | ₪

13,970

25,820

Fair value of the trade warrants | ₪

₪ 2,481

3,173

₪ 3,173

Consideration | ₪

23,269

Financial expenses

₪ 622

₪ (3,892)

$ (1,123)

₪ (33)

₪ (79)

Issued ordinary shares

5,783,437

Non-tradable warrants, share

265,568

265,568

Description of options term

The terms of the options (Series 1): (i) extension of the expiration date options (Series 1) to a date that is 80 days from court approval for such of the exercise period of the options (Series 1) (i.e. August 17, 2017, following court approval), and (ii) reduction in the exercise price of the options (Series 1) from NIS 1.85 per option to NIS 1.20 per option, in accordance with Section 350 of the Israeli Companies Law. On May 29, 2017, the court approved the changes to the options (Series 1). Due to the change in terms, the fair value of the options (Series 1) changed in NIS 2,008. On August 17, 2017 the options (Series 1) expired.

Investors, share

531,136

531,136

Purchase of non-tradable warrants

265,568

265,568

Direct offering | $ / shares

$ 8.10

Agent fees | $

$ 140

Warrants to purchase

969,231

Inintial public offiering of ADS shares

1,292,308

Warrants exercisable, description

Each Listed Warrants is exercisable into one ADS, for a period of five years at an exercise price of US$ 7.50 per warrant.

Unlisted options

341,073

Warrant exercise price | (per share)

₪ 6.5

$ 2.1

₪ 1.20

Over Allotment [Member]

Equity (Textual)

Warrants to purchase

145,385

Inintial public offiering of ADS shares

193,846

Warrants exercisable, description

ADSs at a price of US$ 6.038 per ADS and/or an additional Listed Warrants to purchase 145,385 ADSs, on the same terms as the warrants issued to the public, at a price of US$ 0.007 per warrant.

Listed shares

65,890

Underwriters arrangement [Member] | Non Tradeable Warrants [Member]

Equity (Textual)

Warrants exercisable term

1 year

1 year

Issuance costs | $

$ 204

Number of warrants exercisable | Share

77,538

77,538

Non-tradable warrants, description

The Company issued to the underwriters unlisted warrants to purchase 77,538 ADSs at an exercise price of $8.80 per warrant convertible at a 1:1 ratio and exercisable for a period of four years.

Purchase of non-tradable warrants

7,492

7,492

61,487

Warrants exercisable, description

The investor warrants except they have an exercise price of $10.125 per ADS.

The investor warrants except they have an exercise price of $10.125 per ADS.

Warrant exercise price | $ / shares

$ 12.07

Share-Based Compensation (Detai

Share-Based Compensation (Details) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)	Dec. 31, 2015ILS (₪)
Share-Based Compensation [Abstract]
Research and development	₪ 1,940	$ 560	₪ 253	₪ 523
General and administrative	3,444	993	1,299	795
Total share-based compensation	₪ 5,384	$ 1,553	₪ 1,552	₪ 1,318

Share-Based Compensation (Det43

Share-Based Compensation (Details 1) - ₪ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-Based Compensation [Abstract]
Number of options, Outstanding at beginning of year	5,979,973	5,764,866
Number of options, Options exercised for shares	(696,980)
Number of options, Options forfeited	(166,667)	(2,054,396)
Number of options, Option Expired	(726,512)	(337,000)
Number of options, Granted	6,362,854	2,606,503
Number of options, Outstanding at end of year	10,752,668	5,979,973
Weighted Average Exercise price, Outstanding at beginning of year	₪ 1.25	₪ 1.37
Weighted Average Exercise price, Options exercised for shares	1.16
Weighted Average Exercise price, Options forfeited	0.63	1.43
Weighted Average Exercise price, Option Expired	1.69	1.42
Weighted Average Exercise price, Granted	1.16	1.14
Weighted Average Exercise price, Outstanding at end of year	₪ 1.18	₪ 1.25

Share-Based Compensation (Det44

Share-Based Compensation (Details 2)	12 Months Ended
	Dec. 31, 2017shares
Share Based Compensation [Line Items]
Options outstanding	10,752,668
Weighted average remaining contractual term (years)	8 years 2 months 12 days
Options exercisable	3,219,782
Weighted average remaining contractual term (years)	5 years 9 months 18 days
0.001 - 1.35 [Member]
Share Based Compensation [Line Items]
Options outstanding	8,310,168
Weighted average remaining contractual term (years)	8 years 3 months 19 days
Options exercisable	1,452,782
Weighted average remaining contractual term (years)	4 years 3 months 19 days
1.35 - 1.8 [Member]
Share Based Compensation [Line Items]
Options outstanding	2,010,500
Weighted average remaining contractual term (years)	7 years 8 months 12 days
Options exercisable	1,335,000
Weighted average remaining contractual term (years)	6 years 8 months 12 days
1.8 - 2.1 [Member]
Share Based Compensation [Line Items]
Options outstanding	432,000
Weighted average remaining contractual term (years)	7 years 7 months 6 days
Options exercisable	432,000
Weighted average remaining contractual term (years)	7 years 7 months 6 days
Minimum [Member] | 0.001 - 1.35 [Member]
Share Based Compensation [Line Items]
Exercise price (Range)	0.001
Minimum [Member] | 1.35 - 1.8 [Member]
Share Based Compensation [Line Items]
Exercise price (Range)	1.35
Minimum [Member] | 1.8 - 2.1 [Member]
Share Based Compensation [Line Items]
Exercise price (Range)	1.8
Maximum [Member] | 0.001 - 1.35 [Member]
Share Based Compensation [Line Items]
Exercise price (Range)	1.35
Maximum [Member] | 1.35 - 1.8 [Member]
Share Based Compensation [Line Items]
Exercise price (Range)	1.8
Maximum [Member] | 1.8 - 2.1 [Member]
Share Based Compensation [Line Items]
Exercise price (Range)	2.1

Share-Based Compensation (Det45

Share-Based Compensation (Details 3)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share Based Compensation [Line Items]
Dividend yield (%)	0.00%	0.00%
Expected life of share options (years)	10 years
Minimum [Member]
Share Based Compensation [Line Items]
Expected volatility of the share prices (%)	81.56%	84.05%
Risk-free interest rate (%)	1.94%	1.04%
Expected life of share options (years)		4 years
Maximum [Member]
Share Based Compensation [Line Items]
Expected volatility of the share prices (%)	85.61%	91.60%
Risk-free interest rate (%)	2.52%	2.10%
Expected life of share options (years)		10 years

Share-Based Compensation (Det46

Share-Based Compensation (Details Textual) ₪ / shares in Units, ₪ in Thousands	Jul. 23, 2017shares	Jul. 28, 2016$ / shares	Feb. 28, 2016$ / shares	Mar. 28, 2017shares	Feb. 28, 2017shares	Nov. 23, 2015ILS (₪)₪ / sharesshares	Aug. 16, 2017₪ / shares	Dec. 31, 2017ILS (₪)shares	Dec. 31, 2016ILS (₪)
Share-Based Compensation (Textual)
Options pooled					12,707,971
Fair value of the options, grants | ₪								₪ 10,252	₪ 10,252
Warrant exercise price | (per share)		$ 6.5	$ 2.1				₪ 1.20
Consultant [Member]
Share-Based Compensation (Textual)
Shares issued	7,515				15,000
Consultant [Member] | Tranche one issued in May 2017 [Member]
Share-Based Compensation (Textual)
Shares issued					5,000
Consultant [Member] | Tranche two issued in July 2017 [Member]
Share-Based Compensation (Textual)
Shares issued					5,000
Consultant [Member] | Tranche three issued in November 2017 [Member]
Share-Based Compensation (Textual)
Shares issued					5,000
Board of Directors [Member]
Share-Based Compensation (Textual)
Options pooled					4,207,971
Deputy CEO and CFO [Member]
Share-Based Compensation (Textual)
Options exercisable				500,000		2,658,246
Exercisable ordinary shares				500,000
Number of options granted						2,658,246
Total benefit received from grant | ₪						₪ 3,033
Warrant exercise price | ₪ / shares						₪ 1.286
Deputy CEO and CFO [Member] | January, 2018 [Member]
Share-Based Compensation (Textual)
Options exercisable								310,180
Remaining options expired								297,420
Option expiration date								Feb. 28, 2018
Exercisable ordinary shares								310,180

Taxes on Income (Details)

Taxes on Income (Details) - ILS (₪) ₪ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Taxes on Income (Textual)
Israeli corporate income tax rate		24.00%	25.00%	26.50%
Change in tax rate, description	In January 2016, the Law for Amending the Income Tax Ordinance (No. 216) (Reduction of Corporate Tax Rate), 2016 was approved, which includes a reduction of the corporate tax rate from 26.5% to 25%, effective from January 1, 2016.		The Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018.
Carryforward operating losses		₪ 35,085

Contingent Liabilities and Co48

Contingent Liabilities and Commitments (Details) - ILS (₪) ₪ in Thousands	Sep. 01, 2015	Dec. 31, 2017
Contingent Liabilities and Commitments (Textual)
Restricted bank deposit to secure the rent payment		₪ 120
Minimum lease agreement term	3 years
Commitments agreement, description		Israel-United States Binational Industrial Research and Development Foundation (BIRD) for the support of research and development activities. The Company is obligated to pay royalties to BIRD, amounting to 5% of the gross sales of the products and other related revenues developed from such activities, up to an amount of 150% from the grant received from BIRD by the Company indexed to the U.S. consumer price index.
Future minimum monthly lease payments		₪ 183
Restricted bank deposit to secure credit card payments		185
Payment of rental and administration fee	₪ 34
Agregate grant value received		₪ 120

Balances and Transactions wit49

Balances and Transactions with Related Parties (Details) ₪ in Thousands, $ in Thousands	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)
Disclosure of transactions between related parties [line items]
Other payables	₪ 12	$ 3	₪ 14
Key management personnel [Member]
Disclosure of transactions between related parties [line items]
Other payables	425	123	318
Total	425	123	318
Other related parties [Member]
Disclosure of transactions between related parties [line items]
Other payables	827	238	805
Total	₪ 827	$ 238	₪ 805

Balances and Transactions wit50

Balances and Transactions with Related Parties (Details 1) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)People	Dec. 31, 2017USD ($)People	Dec. 31, 2016ILS (₪)People	Dec. 31, 2015ILS (₪)People
Balances and Transactions with Related Parties [Abstract]
Number of people	5	5	7	5
Short-term employee benefits (includes Company's CEO in 2015, 2016 and 2017), Amount	₪ 7,816	$ 2,254	₪ 6,040	₪ 3,423

Balances and Transactions wit51

Balances and Transactions with Related Parties (Details 2) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)People	Dec. 31, 2017USD ($)People	Dec. 31, 2016ILS (₪)People	Dec. 31, 2015ILS (₪)People
Disclosure of transactions between related parties [line items]
No. of people	8	8	5	7
Amount	₪ 682	$ 197	₪ 513	₪ 921
Key management personnel and related parties [Member]
Disclosure of transactions between related parties [line items]
No. of people				2
Amount | ₪				₪ 444
Directors' fees [Member]
Disclosure of transactions between related parties [line items]
No. of people	8	8	5	5
Amount	₪ 682	$ 197	₪ 513	₪ 477

Balances and Transactions wit52

Balances and Transactions with Related Parties (Details 3) ₪ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016ILS (₪)	Dec. 31, 2015ILS (₪)
Key management personnel [Member]
Disclosure of transactions between related parties [line items]
Research and development expenses	₪ 634	$ 183	₪ 1,063	₪ 713
General and administrative expenses	2,014	581	2,317	921
Total	2,648	764	3,380	1,634
Related parties [Member]
Disclosure of transactions between related parties [line items]
Research and development expenses	2,661	767	1,544	1,422
General and administrative expenses	2,507	724	1,116	811
Total	₪ 5,168	$ 1,491	₪ 2,660	₪ 2,233

Subsequent Events (Details)

Subsequent Events (Details) ₪ / shares in Units, $ / shares in Units, ₪ in Thousands, $ in Thousands	Sep. 07, 2017ILS (₪)shares	Sep. 07, 2017USD ($)shares	Jul. 28, 2016ILS (₪)	Jul. 28, 2016$ / shares	Feb. 28, 2016$ / shares	Aug. 16, 2017₪ / shares	Dec. 31, 2017ILS (₪)shares	Dec. 31, 2017USD ($)$ / sharesshares
Subsequent Events (Textual)
Purchase of non-tradable warrants	265,568	265,568
Net of issuance costs | ₪	₪ 13,970		₪ 25,820
Agent fees | $		$ 140
Warrant exercise price | (per share)				$ 6.5	$ 2.1	₪ 1.20
January 29, 2018 [Member]
Subsequent Events (Textual)
Warrant exercise price | $ / shares								$ 10.31
January 29, 2018 [Member] | Investors [Member]
Subsequent Events (Textual)
Direct offering | $ / shares								$ 8.25
Purchase of non-tradable warrants							24,242	24,242
Net of issuance costs							₪ 12,500	$ 3,600
Agent fees | $								$ 305
Investors unregistered non-tradable warrants							266,667	266,667
Aggregate shares							484,848	484,848
Warrant exercise price | $ / shares								$ 12